Citations

Mayo Clinic

Showing 10 of 108523 citations.

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
Tefferi, Ayalew , Barosi, Giovanni , Hernández‐Boluda, Juan Carlos , Bose, Prithviraj , Döhner, Konstanze , Gangat, Naseema , Garcia, Jacqueline S. , Gisslinger, Heinz , Gupta, Vikas , Harrison, Claire , Loscocco, Giuseppe Gaetano , Mora, Barbara , Odenike, Olatoyosi, Pardanani, Animesh , Patel, Anand , Pemmaraju, Naveen , Rampal, Raajit K. , Sirhan, Shireen , Vachhani, Pankit , Vannucchi, Alessandro M., Barbui, Tiziano , Hernández-Boluda, Juan Carlos , Bose, Prithviraj , Gangat, Naseema , Garcia, Jacqueline S , Gupta, Vikas , Hexner, Elizabeth , Hobbs, Gabriela S , Koschmieder, Steffen , Kuykendall, Andrew , Loscocco, Giuseppe Gaetano , Mascarenhas, John , Masarova, Lucia , Mesa, Ruben , Oh, Stephen T , Patel, Anand , Pemmaraju, Naveen , Rambaldi, Alessandro , Szuber, Natasha , Vachhani, Pankit , Barbui, Tiziano , Passamonti, Francesco , Ellis, Martin H. , Gotlib, Jason , Guglielmelli, Paola , Hexner, Elizabeth O. , Hobbs, Gabriela , Kiladjian, Jean‐Jacques , Koschmieder, Steffen , Kröger, Nicolaus , Mascarenhas, John , Masárová, Lucia , Mesa, Ruben A. , Odenike, Olatoyosi , Oh, Stephen T. , Rambaldi, Alessandro , Szuber, Natasha , Talpaz, Moshe

Blood | August 8, 2024 | Volume: 144 | Issue: 17 | Pages: 1813-1820

10.1182/blood.2024025802 | PMID 39116296 Get It

Abstract With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead authors on the 2013 edition of the International Working Group–European LeukemiaNet (IWG-ELN) response criteria in MF were summoned to revise their document with the intent to (1) account for gender-specific differences in determining hemoglobin levels for eligibility criteria; (2) revise the definition of transfusion-dependent anemia (TDA) based on current restrictive transfusion practices; and (3) provide a structurally simple and easy to apply response criteria that are sensitive enough to detect efficacy signals (minor response) and also account for major responses. The initial draft of the 2024 IWG-ELN proposed criteria was subsequently circulated around a wider group of international experts and their feedback incorporated. The proposed articles include new definitions for TDA (≥3 units in the 12 weeks before study enrollment) and hemoglobin thresholds for eligibility criteria (<10 g/dL for women and <11 g/dL for men). The revised document also provides separate (TDA vs non-TDA) and graded (major vs minor response) response criteria while preserving the requirement for a 12-week period of screening and observation on treatment.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
Palmisiano, Neil , Lee, Ju‐Whei , Claxton, David F. , Paietta, Elisabeth , Park, Jae H. , Podoltsev, Nikolai A. , Atallah, Ehab , Schaar, Dale , Dinner, Shira, Webster, Jonathan , Luger, Selina M. , Litzow, Mark R. , Palmisiano, Neil D , Alkhateeb, Hassan B , Podoltsev, Nikolai , Atallah, Ehab L , Webster, Jonathan A , Luger, Selina M , Claxton, David F , Alkhateeb, Hassan B.

eJHaem | August 8, 2024 | Volume: 5 | Issue: 5 | Pages: 951-956

10.1002/jha2.991 | PMID 39415930 Get It

AbstractIntroductionRelapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B‐ and T‐ALL suggests synergy of venetoclax (VEN) with vincristine (VCR). We designed a phase I/II trial (EA9152) of the combination of L‐VCR and VEN for patients with r/r B‐or T‐cell ALL or LL. Here, we report the safety and efficacy outcomes of the phase I portion of this trial (NCT03504644).MethodsIn a 3+3 dose escalation design, r/r ALL subjects were given single‐agent VEN doses reaching 400, 600, or 800 mg for the three respective dose levels. Weekly L‐VCR at 2.25 mg/m2 IV was started on D15 of cycle 1. The primary phase I objective was to determine the maximum tolerated dose (MTD) of the combination.ResultsAmong the 18 patients in phase I, grade ≥ 3 treatment‐related adverse events were reported in 89% of treated patients. Two patients (two of three) at dose level 3 experienced dose‐limiting toxicities. Therefore, the MTD of the combination was determined to be dose level 2 (VEN 600 mg). Twenty‐two percent of evaluable patients (N = 4) achieved a complete response, with two of them showing no evidence of measurable residual disease (MRD).ConclusionThe combination of VEN and L‐VCR was found to be safe for patients with r/r ALL and encouraging preliminary efficacy, including MRD negative responses. With the removal of L‐VCR from the US market, the phase 2 portion of this trial is actively enrolling with vincristine sulfate.
Economic Impact of Postoperative Urinary Retention in the US Hospital Setting
Marks‐Anglin, Arielle , Turzhitsky, Vladimir , Mark, Robert J., Rosales, Aurelio Otero, Bailey, Nathaniel W., Jiang, Yiling , Abueg, Joseph, Hofer, Ira , Wang, Weijia, Bailey, Nathaniel W., Weingarten, Toby N.

Journal of Health Economics and Outcomes Research | August 8, 2024 | Volume: 11 | Issue: 2 | Pages: No page available

10.36469/001c.121641 | PMID 39267889 Get It

Background Postoperative urinary retention (POUR) is a common and distressing surgical complication that may be associated with the pharmacological reversal technique of neuromuscular blockade (NMB). Objective This study aimed to investigate the impact that POUR has on medical charges. Methods This was a retrospective observational study of adult patients undergoing select surgeries who were administered neuromuscular blockade agent (NMBA), which was pharmacologically reversed between February 2017 and November 2021 using data from the PINC-AI™ Healthcare Database. Patients were divided into 2 groups: those experiencing POUR (composite of retention of urine, insertion of temporary indwelling bladder catheter, insertion of non-indwelling bladder catheter) during index hospitalization following surgery and those without POUR. Surgeries in inpatient and outpatient settings were analyzed separately. A cross-sectional comparison was performed to report total hospital charges for the 2 groups. Furthermore, patients experiencing subsequent POUR events within three days after discharge from index hospitalization were studied. Results A total of 330 838 inpatients and 437 063 outpatients were included. POUR developed in 13 020 inpatients and 2756 outpatients. Unadjusted results showed that POUR was associated with greater charges in both inpatient ($92 529 with POUR vs $78 556 without POUR, p < .001) and outpatient ($48 996 with POUR vs $35 433 without POUR, p < .001) settings. After adjusting for confounders, POUR was found to be associated with greater charges with an overall mean adjusted difference of $10 668 (95% confidence interval [CI] $95 760-$11 760, p < .001) in inpatient and $13 160 (95% CI $11 750-$14 571, p < .001) in outpatient settings. Charges associated with subsequent POUR events following discharge ranged from $9418 inpatient charges to $1694 outpatient charges. Conclusions Surgical patients who were pharmacologically reversed for NMB and developed a POUR event incurred greater charges than patients without POUR. These findings support the use of NMB reversal agents associated with a lower incidence of POUR.
Design and validation of the ADNI MR protocol
Arani, Arvin , Borowski, Bret, Felmlee, John, Thomas, David L. , Gunter, Jeffrey L. , Stables, Lara, Jung, Youngkyoo , Tosun, Duygu , Weiner, Michael W. , Jack, Clifford R. , Initiative, for the Alzheimer's Disease Neuroimaging, Tosun, Duygu , Jack, Clifford R , Arani, Arvin , Tosun, Duygu , Reid, Robert I. , Buckner, Randy L. , Initiative, for the Alzheimer's Disease Neuroimaging

Alzheimer's & Dementia | August 8, 2024 | Volume: 20 | Issue: 9 | Pages: 6615-6621

10.1002/alz.14162 | PMID 39115941 Get It

AbstractPhase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI4) magnetic resonance imaging (MRI) protocols aim to maintain longitudinal consistency across two decades of data acquisition, while adopting new technologies. Here we describe and justify the study's design and targeted biomarkers. The ADNI4 MRI protocol includes nine MRI sequences. Some sequences require the latest hardware and software system upgrades and are continuously rolled out as they become available at each site. The main sequence additions/changes in ADNI4 are: (1) compressed sensing (CS) T1‐weighting, (2) pseudo‐continuous arterial spin labeling (ASL) on all three vendors (GE, Siemens, Philips), (3) multiple‐post‐labeling‐delay ASL, (4) 1 mm3 isotropic 3D fluid‐attenuated inversion recovery, and (5) CS 3D T2‐weighted. ADNI4 aims to help the neuroimaging community extract valuable imaging biomarkers and provide a database to test the impact of advanced imaging strategies on diagnostic accuracy and disease sensitivity among individuals lying on the cognitively normal to impaired spectrum.Highlights A summary of MRI protocols for phase four of the Alzheimer's Disease Neuroimaging Initiative (ADNI 4). The design and justification for the ADNI 4 MRI protocols. Compressed sensing and multi‐band advances have been applied to improve scan time. ADNI4 protocols aim to streamline safety screening and therapy monitoring. The ADNI4 database will be a valuable test bed for academic research.
Reply by Authors
Trost, L., Mulhall, J., Trost, Landon , Hellstrom, Wayne J.G.

Journal of Urology | August 8, 2024 | Volume: 212 | Issue: 3 | Pages: 480-481

10.1097/ju.0000000000004112 | PMID 39115124 Get It

Reply by Authors
Trost, Landon , Mulhall, J., Hellstrom, Wayne J.G.

Journal of Urology | August 8, 2024 | Volume: 212 | Issue: 3 | Pages: 481-482

10.1097/ju.0000000000004109 | PMID 39115129 Get It

Creation of a Novel Classification System (PTNM) for Peyronie’s Disease and Penile Curvature Using Evidence-Based Criteria
Trost, Landon , Mulhall, John P. , Hellstrom, Wayne J.G.

Journal of Urology | August 8, 2024 | Volume: 212 | Issue: 3 | Pages: 470-482

10.1097/ju.0000000000004072 | PMID 39115123 Get It

Belonging, Affirmation, Safety, and Efficacy (BASE): An Integrative Model for Shame Resilience, Social Support, and Humor in r/hemorrhoid
Amangalieva, Gulmira , Britt, Rebecca K. , Carmack, Heather J. , Holiday, Steven , Ivic, Rebecca K

Health Communication | August 8, 2024 | Volume: 40 | Issue: 6 | Pages: 1078-1089

10.1080/10410236.2024.2386714 | PMID 39114976 Get It

Persistent hypoxemia in a child with medulloblastoma following a third autologous stem cell transplant
Holthe, Jordan , Boesch, Paul, Kohorst, Mira A. , Schwartz, Jonathan, Boesch, Paul, Ferdjallah, Asmaa

Pediatric Pulmonology | August 8, 2024 | Volume: 59 | Issue: 12 | Pages: 3686-3691

10.1002/ppul.27194 | PMID 39115448 Get It

Polygenic Risk and Coronary Artery Disease Severity
Sherafati, Alborz , Norland, Kristján , Naderian, Mohammadreza , Schaid, Daniel J. , Kullo, Iftikhar J. , Kullo, Iftikhar J , Naderian, Mohammadreza

Circulation: Genomic and Precision Medicine | August 8, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circgen.123.004470 | PMID 39114909 Get It

BACKGROUND: Coronary atherosclerotic burden and adverse coronary heart disease events are related phenotypes with likely shared genetic cause. METHODS: We analyzed 6021 patients with available coronary angiography, genotyping, and exome sequencing data. We tested for associations of polygenic risk scores for coronary heart disease (PRS CHD ) with multiple measures of coronary artery disease (CAD) severity. We assessed the joint associations of PRS CHD and pathogenic/likely pathogenic variants in 3 familial hypercholesterolemia genes, with CAD severity. We performed mediation analyses to explore whether CAD severity mediated the association of PRS CHD with prevalent coronary heart disease and incident myocardial infarction. RESULTS: A 1-SD increase in PRS CHD was associated with multiple measures of CAD severity, including the log Gensini score (β, 0.31 [95% CI, 0.28–0.33]). Carrying a pathogenic/likely pathogenic familial hypercholesterolemia variant was associated with a higher log Gensini score after adjustment for PRS CHD (β, 0.21 [95% CI, 0.03–0.38]). A 1-SD increase in PRS CHD was associated with incident myocardial infarction over a mean follow-up of 9.2 years (hazard ratio, 1.20 [95% CI, 1.13–1.27]; P =5×10 − 10 ), and the Gensini score mediated 90% of this association. CONCLUSIONS: PRS CHD was associated with multiple measures of CAD severity. The association of PRS CHD with incident myocardial infarction was almost fully mediated by CAD severity, indicating a considerable genetic overlap between the 2 phenotypes.